Reviewed by Reviewed by Renuka Tahelyani Updated 13:00 EDT October 11, 2026 Share Share Share Back to Top Injective [INJ] gained 10% in the early hours of the 10th of October as bullish trading activity picked up
Perpetual buying pressure and spot exchange outflows supported the outlook, with traders showing renewed interest in the asset
Alongside those moves, Injective’s updated white paper and ongoing exchange-traded fund (ETF) applications offered potential catalysts
Across exchanges, INJ’s Taker Buy/Sell Ratio reached 1.14 over the preceding four hours. A reading above 1 indicates that taker buying volume exceeded taker selling volume, pointing to stronger aggressive buying
However, the ratio measures executed trading volume rather than the number of outstanding long and short positions
The exchange breakdown showed buying accounted for more than half of recorded volume on several major venues. These included Binance, Bybit, Gate, BingX, Bitunix, and Hyperliquid
That supported the bullish reading across multiple platforms. The next question is how much exposure traders added alongside those purchases
INJ’s OI-Weighted Funding Rate stood at a positive 0.0160%, indicating that longs were paying shorts. That reading supported a bullish positioning bias, without establishing that long positions outnumbered shorts
Meanwhile, Open Interest increased by $34.88 million to $164.24 million over 24 hours, showing a larger pool of outstanding contracts
Spot exchange flows offered another supportive signal. Cumulative Spot Netflow reached approximately -$1.6 million over five days. At press time on the 11th of October, Spot Netflow stood at -$311,000, the largest net outflow since the 9th
Negative Netflows meant more INJ left exchanges than entered them. Those withdrawals could suggest holders were moving tokens into custody, potentially reducing readily available exchange supply
Still, exchange withdrawals alone cannot confirm fresh purchases. Together, the readings supported the bullish outlook while leaving buyers’ intentions partly open
Beyond trading activity, Injective published an updated white paper outlining its finance-focused development plans. Its regulatory work included publication of an INJ white paper under Europe’s Markets in Crypto-Assets Regulation (MiCA)
That process was separate from U.S. Securities and Exchange Commission (SEC) oversight, rather than a regulatory channel between the two
Meanwhile, 21Shares and Canary pursued INJ ETF applications, offering another potential source of investor interest
Injective CEO Eric Chen had suggested a launch could come before 2027, although that remained his expectation. Overall, these developments could help sustain interest. Further upside would still depend on demand holding beyond the initial rally
Olayiwola Dolapo is a Crypto Research Analyst at AMBCrypto, driven by a mission to make the digital asset space more transparent and understandable for all. His journey was catalyzed by an early experience in the market that underscored the importance of deep, foundational knowledge—a principle that now guides his professional work
